Posted On: 05/29/2014 7:51:17 AM
Post# of 5949
Re: BULLDOUGHZER #1439
GM, BD! Angel has followed through on every step, as promised, and I am expecting some really BIG things in the coming weeks. Now that we are current, the official name/ticker change comes next. Angel promised a BIG juicy PR to accompany that. Angel's email (sent last Friday, 7:03pm) has me very fired up on what is to come next, (excerpt):
"To this end, as time progresses I will key up more on strategy, opportunities, and industry markers. I will talk less on products to come, and more on products released. We will highlight more accomplishments, and discuss fewer promises. This is a shift away from "pink sheet conjecture" with a greater focus on "big board behavior". For who we are as a company, we had the wrong advisors clinging on in 2012, the remnants of a sordid RIGH past that I was not involved in. That era is over. The BGMT, BMED, or BUDG era is now set to begin. Of course we will engage in conversations about development, market share, and opportunity. We are still a young company with much growth ahead. Highlighting all of this is important to shareholders. Our DNA, who we are, and how we function, are key factors that differentiate our opportunity from others in the medical marijuana space. This dialogue will continue -- with you, with other shareholders, and publicly."
"To this end, as time progresses I will key up more on strategy, opportunities, and industry markers. I will talk less on products to come, and more on products released. We will highlight more accomplishments, and discuss fewer promises. This is a shift away from "pink sheet conjecture" with a greater focus on "big board behavior". For who we are as a company, we had the wrong advisors clinging on in 2012, the remnants of a sordid RIGH past that I was not involved in. That era is over. The BGMT, BMED, or BUDG era is now set to begin. Of course we will engage in conversations about development, market share, and opportunity. We are still a young company with much growth ahead. Highlighting all of this is important to shareholders. Our DNA, who we are, and how we function, are key factors that differentiate our opportunity from others in the medical marijuana space. This dialogue will continue -- with you, with other shareholders, and publicly."
(0)
(0)Scroll down for more posts ▼
